REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

18/02/2019 17:15

RNS Number : 4082Q
GlaxoSmithKline PLC
18 February 2019
 


 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics and Compliance




c)


Initial notification/
amendment


Initial Notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  
 




b)


Nature of the transaction


The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.0000


15,914 (Deferred)


 




 


£0.0000


9,392 (Matching)


 




 


 


 


 




d)


Aggregated information


 




Aggregated volume Price


25,306
£0.0000




e)


Date of the transaction


2019-02-15




f)


Place of the transaction
 


n/a




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')


 




a)


Name


Mr N Hirons


 




b)


Position/status


SVP, Global Ethics and Compliance


 




c)


Initial notification/
amendment


Initial Notification


 




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


 




a)


Name


GlaxoSmithKline plc


 




b)


LEI


5493000HZTVUYLO1D793


 




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted


 




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  


 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.


 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.9006


7,500 (Deferred)


 




 


£15.9006


4,425 (Matching)


 




 


 


 


 




d)


Aggregated information


 


 




Aggregated volume
Price


11,925
£15.9006


 




e)


Date of the transaction


2019-02-15


 




f)


Place of the transaction
 


London Stock Exchange (XLON)


 



 
 
 
 
 
 
 



 
 
 
 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial Notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  
 




b)


Nature of the transaction


The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.0000


20,254 (Deferred)


 




 


£0.0000


11,952 (Matching)


 




 


 


 


 




d)


Aggregated information


 




Aggregated volume Price


32,206
£0.0000




e)


Date of the transaction


2019-02-15




f)


Place of the transaction
 


n/a




 
 
 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')


 




a)


Name


Mr D Redfern


 




b)


Position/status


Chief Strategy Officer


 




c)


Initial notification/
amendment


Initial Notification


 




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


 




a)


Name


GlaxoSmithKline plc


 




b)


LEI


5493000HZTVUYLO1D793


 




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted


 




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  


 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.


 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.878


9,545 (Deferred)


 




 


£15.878


5,631 (Matching)


 




 


 


 


 




d)


Aggregated information


 


 




Aggregated volume
Price


15,176
£15.878


 




e)


Date of the transaction


2019-02-15


 




f)


Place of the transaction
 


London Stock Exchange (XLON)


 



 
 
 
 
 
 
 



 
 
 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms C Thomas




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial Notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  




b)


Nature of the transaction


The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.0000


29,636 (Deferred)


 




 


£0.0000


17,488 (Matching)


 




 


 


 


 




d)


Aggregated information


 




Aggregated volume Price


47,124
£0.0000




e)


Date of the transaction


2019-02-15




f)


Place of the transaction
 


n/a




 
 
 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms C Thomas




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial Notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial  instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
  




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£15.8753


13,951 (Deferred)


 




 


£15.8753


8,232 (Matching)


 




 


 


 


 




d)


Aggregated information


 




Aggregated volume Price


22,183
£15.8753




e)


Date of the transaction


2019-02-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDVLFFKLFFBBF